Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Vyalev™ (foscarbidopa/foslevodopa) – New drug approval

October 17, 2024 -  AbbVie announced the FDA approval of Vyalev (foscarbidopa/ foslevodopa), for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD).

Download PDF

Rx navigation